{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Agent Affecting Nervous System[C78272]|Anesthetic Agent" in comments (approximate match)
Status:
US Previously Marketed
Source:
FURACIN OTIC DROPS DIPERODON HYDROCHLORIDE by NORWICH
(1961)
Source URL:
First marketed in 1937
Source:
Diothane by Merrell
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Diperodon is one of several phenylurethane derivatives of dialkyl amino alcohols which have demonstrated significant local anaesthetic activity.
Status:
US Previously Marketed
Source:
PENTOTHAL by ABBOTT
(1959)
Source URL:
First marketed in 1934
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Sodium thiopental (also known as Sodium Pentothal, thiopental) was discovered in 1930s by investigators working for Abbott Laboratories. Thiopental sodium was used for the induction of general anesthesia and is used as an adjunct to provide hypnosis during balanced anesthesia with other anesthetic agents, including analgesics and muscle relaxants. Thiopental sodium was also used as an adjunct for control of convulsive disorders of various etiology, including those caused by local anesthetics. Finally, thiopental sodium had been used to reduce the intracranial pressure in patients with increased intracranial pressure, if controlled ventilation is provided. Nevertheless, these prescriptions of drug were discontinued. In addition, this drug was banned for use in US executions. Thiopental sodium acts through the CNS with particular activity in the mesencephalic reticular activating system. It was shown, that mechanism of action of sodium thiopental via GABAA receptor. Thiopental binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Status:
US Previously Marketed
First marketed in 1933
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Piperocaine (Metycaine) is a local anesthetic drug. It is an ester and primarily is a sodium channel blocker. Piperocaine can partially inhibit dopamine. It is known as a alpha-1-proteinase inhibitor. Used in the form of its hydrochloride as a local or spinal anesthetic and in dental anesthesia. Can cause toxic reactions. Piperocaine Hydrochloride is in the list of Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, FDA Act. Piperocaine hydrochloride is a small, white odorless crystals or a white crystalline powder, stable in air, freely soluble in water, alcohol and chloroform.
Status:
US Previously Marketed
First marketed in 1920
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Butacaine is a local anesthetic. It should not be used with people who have a history of allergies due to the possibility of anaphylactic shock.
Status:
US Previously Marketed
First marketed in 1907
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Amylocaine (trade name Stovaine) is a local anesthetic, that was widely used for spinal anesthesia in Caesarean section. The dose used would produce anesthesia for up to 1 h. Reports of the use of spinal analgesia for abdominal and perineal surgery in infants are found from several centers during the first half of the twentieth century. However, this agent often fails to provide good maternal sensory block and currently, Amylocaine has been replaced with new anesthetics.
Status:
US Previously Marketed
Source:
PROCAINE HYDROCHLORIDE by GD SEARLE LLC
(1982)
Source URL:
First marketed in 1905
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine. Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
Status:
US Previously Marketed
Source:
PROCAINE HYDROCHLORIDE by GD SEARLE LLC
(1982)
Source URL:
First marketed in 1905
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine. Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.
Status:
US Previously Marketed
Source:
Holocaine
(1898)
Source URL:
First marketed in 1898
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Phenacaine (UNII: V3M4D317W8) also known as holocaine is a local anesthetic used in ophthalmic medicine. Like other local anesthetics it inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca2+-ATPase (ATP phosphohydrolase) and cyclic nucleotide phosphodiesterases (3',5'-cyclic-nucleotide 5'-nucleotidohydrolase) from brain and heart. Basal activities of these enzymes in the absence of calmodulin are relatively unaffected by concentrations of local anesthetics that strongly inhibit the specific stimulation by calmodulin. Increasing calmodulin, but not Ca2+, overcomes the inhibitory action of the local anesthetics on brain phosphodiesterase. However, excess calmodulin does not fully restore activity of erythrocyte CA2+-stimulated ATPase. Although the mechanism(s) by which the local anesthetics act is unclear, they inhibit binding of 125I-labeled calmodulin to the erythrocyte membrane. Antagonism of calmodulin provides a molecular mechanism that may explain the inhibition of many Ca2+-dependent cellular processes by local anesthetics--e.g., Ca2+ transport, exocytosis, excitation-contraction coupling, non-muscle-cell motility, and aggregation. Phenacaine hydrochloride is registered by FDA as an anorectal drug product and is in the list of OTC active ingredients. The Ointment Ophthalmic Holocaine and Epinephrine (1.5% phenacaine hydrochloride) were distributed by National Drug Co., a corporation, Philadelphia, Pa. and in 1939 and was alleged to be misbranded since it contained less phenacaine hydrochloride than indicated by the labeling.
Status:
US Previously Marketed
Source:
Holocaine
(1898)
Source URL:
First marketed in 1898
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Phenacaine (UNII: V3M4D317W8) also known as holocaine is a local anesthetic used in ophthalmic medicine. Like other local anesthetics it inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca2+-ATPase (ATP phosphohydrolase) and cyclic nucleotide phosphodiesterases (3',5'-cyclic-nucleotide 5'-nucleotidohydrolase) from brain and heart. Basal activities of these enzymes in the absence of calmodulin are relatively unaffected by concentrations of local anesthetics that strongly inhibit the specific stimulation by calmodulin. Increasing calmodulin, but not Ca2+, overcomes the inhibitory action of the local anesthetics on brain phosphodiesterase. However, excess calmodulin does not fully restore activity of erythrocyte CA2+-stimulated ATPase. Although the mechanism(s) by which the local anesthetics act is unclear, they inhibit binding of 125I-labeled calmodulin to the erythrocyte membrane. Antagonism of calmodulin provides a molecular mechanism that may explain the inhibition of many Ca2+-dependent cellular processes by local anesthetics--e.g., Ca2+ transport, exocytosis, excitation-contraction coupling, non-muscle-cell motility, and aggregation. Phenacaine hydrochloride is registered by FDA as an anorectal drug product and is in the list of OTC active ingredients. The Ointment Ophthalmic Holocaine and Epinephrine (1.5% phenacaine hydrochloride) were distributed by National Drug Co., a corporation, Philadelphia, Pa. and in 1939 and was alleged to be misbranded since it contained less phenacaine hydrochloride than indicated by the labeling.
Status:
US Previously Marketed
Source:
beta-Eucaine by E. Schering, Berlin, Germany (Scherlng & Giatz, New York).
(1897)
Source URL:
First marketed in 1897
Source:
beta-Eucaine by E. Schering, Berlin, Germany (Scherlng & Giatz, New York).
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)